MA54940B1 - Dérivés d'acides aminés pour le traitement de maladies inflammatoires - Google Patents
Dérivés d'acides aminés pour le traitement de maladies inflammatoiresInfo
- Publication number
- MA54940B1 MA54940B1 MA54940A MA54940A MA54940B1 MA 54940 B1 MA54940 B1 MA 54940B1 MA 54940 A MA54940 A MA 54940A MA 54940 A MA54940 A MA 54940A MA 54940 B1 MA54940 B1 MA 54940B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- amino acid
- acid derivatives
- inflammatory diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La présente invention concerne certains dérivés d'acides aminés qui inhibent l'activation de NF-kB et sont par conséquent utiles pour le traitement de maladies inflammatoires. L'invention concerne également des compositions pharmaceutiques contenant de tels composés et des procédés de préparation de tels composés.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795549P | 2019-01-22 | 2019-01-22 | |
| US201962871951P | 2019-07-09 | 2019-07-09 | |
| PCT/US2020/014636 WO2020154420A2 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
| EP20708296.7A EP3924349B1 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54940A MA54940A (fr) | 2021-12-22 |
| MA54940B1 true MA54940B1 (fr) | 2025-09-30 |
Family
ID=69726748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54940A MA54940B1 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20220081415A1 (fr) |
| EP (1) | EP3924349B1 (fr) |
| JP (2) | JP7784708B2 (fr) |
| KR (1) | KR20210141930A (fr) |
| CN (1) | CN113614074A (fr) |
| AU (2) | AU2020211980B2 (fr) |
| BR (1) | BR112021014372A2 (fr) |
| CA (1) | CA3127246A1 (fr) |
| CL (1) | CL2021001944A1 (fr) |
| CO (1) | CO2021010931A2 (fr) |
| DK (1) | DK3924349T3 (fr) |
| EC (1) | ECSP21062210A (fr) |
| ES (1) | ES3038582T3 (fr) |
| FI (1) | FI3924349T3 (fr) |
| HR (1) | HRP20251058T1 (fr) |
| HU (1) | HUE072722T2 (fr) |
| IL (1) | IL284980A (fr) |
| LT (1) | LT3924349T (fr) |
| MA (1) | MA54940B1 (fr) |
| MD (1) | MD3924349T2 (fr) |
| MX (1) | MX2021008748A (fr) |
| PH (1) | PH12021551760A1 (fr) |
| PL (1) | PL3924349T3 (fr) |
| PT (1) | PT3924349T (fr) |
| RS (1) | RS67095B1 (fr) |
| SG (1) | SG11202107977TA (fr) |
| SI (1) | SI3924349T1 (fr) |
| SM (1) | SMT202500289T1 (fr) |
| WO (1) | WO2020154420A2 (fr) |
| ZA (1) | ZA202105229B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019389168A1 (en) | 2018-11-30 | 2021-06-24 | Comet Therapeutics, Inc. | Pantetheine derivatives and uses thereof |
| WO2025144874A1 (fr) | 2023-12-24 | 2025-07-03 | The Roskamp Institute | Inhibiteurs puissants de nf-kb destinés au traitement de maladies inflammatoires |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU8875398A (en) * | 1997-08-29 | 1999-03-22 | Proteus Molecular Design Ltd | 1-amino-7-isoquinoline derivatives as serine protease inhibitors |
| US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
| WO2009086303A2 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| WO2009121018A2 (fr) * | 2008-03-27 | 2009-10-01 | University Of Kentucky Research Foundation | Comédicaments opioïde-nornicotine destinés à la gestion de la douleur |
| ES2612731T3 (es) | 2008-08-19 | 2017-05-18 | Janssen Pharmaceutica Nv | Antagonistas de receptores al frío de mentol |
| US20120046357A1 (en) * | 2009-05-01 | 2012-02-23 | Profectus Biosciences, Inc. | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) |
-
2020
- 2020-01-22 ES ES20708296T patent/ES3038582T3/es active Active
- 2020-01-22 PH PH1/2021/551760A patent/PH12021551760A1/en unknown
- 2020-01-22 FI FIEP20708296.7T patent/FI3924349T3/fi active
- 2020-01-22 PL PL20708296.7T patent/PL3924349T3/pl unknown
- 2020-01-22 US US17/424,455 patent/US20220081415A1/en active Pending
- 2020-01-22 MX MX2021008748A patent/MX2021008748A/es unknown
- 2020-01-22 CN CN202080021880.4A patent/CN113614074A/zh active Pending
- 2020-01-22 BR BR112021014372-6A patent/BR112021014372A2/pt unknown
- 2020-01-22 CA CA3127246A patent/CA3127246A1/fr active Pending
- 2020-01-22 PT PT207082967T patent/PT3924349T/pt unknown
- 2020-01-22 HU HUE20708296A patent/HUE072722T2/hu unknown
- 2020-01-22 JP JP2021543302A patent/JP7784708B2/ja active Active
- 2020-01-22 MA MA54940A patent/MA54940B1/fr unknown
- 2020-01-22 MD MDE20211218T patent/MD3924349T2/ro unknown
- 2020-01-22 SI SI202030657T patent/SI3924349T1/sl unknown
- 2020-01-22 SM SM20250289T patent/SMT202500289T1/it unknown
- 2020-01-22 WO PCT/US2020/014636 patent/WO2020154420A2/fr not_active Ceased
- 2020-01-22 AU AU2020211980A patent/AU2020211980B2/en active Active
- 2020-01-22 RS RS20250796A patent/RS67095B1/sr unknown
- 2020-01-22 EP EP20708296.7A patent/EP3924349B1/fr active Active
- 2020-01-22 KR KR1020217026302A patent/KR20210141930A/ko not_active Ceased
- 2020-01-22 HR HRP20251058TT patent/HRP20251058T1/hr unknown
- 2020-01-22 LT LTEPPCT/US2020/014636T patent/LT3924349T/lt unknown
- 2020-01-22 SG SG11202107977TA patent/SG11202107977TA/en unknown
- 2020-01-22 DK DK20708296.7T patent/DK3924349T3/da active
-
2021
- 2021-07-20 IL IL284980A patent/IL284980A/en unknown
- 2021-07-22 CL CL2021001944A patent/CL2021001944A1/es unknown
- 2021-07-23 ZA ZA2021/05229A patent/ZA202105229B/en unknown
- 2021-08-19 CO CONC2021/0010931A patent/CO2021010931A2/es unknown
- 2021-08-20 EC ECSENADI202162210A patent/ECSP21062210A/es unknown
-
2025
- 2025-01-31 JP JP2025014903A patent/JP2025062004A/ja active Pending
- 2025-12-18 AU AU2025283544A patent/AU2025283544A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57908B1 (fr) | Composés macrocycliques substitués et méthodes de traitement associées | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| WO2003104217A3 (fr) | Promedicaments d'acides amines excitateurs | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
| MA44851B1 (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
| MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
| MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques | |
| MA54940B1 (fr) | Dérivés d'acides aminés pour le traitement de maladies inflammatoires | |
| MA43960B1 (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA51558B1 (fr) | Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires | |
| MX2025000151A (es) | Agonistas de trpml1 con oxazol y usos de los mismos | |
| MA62148B1 (fr) | Inhibiteur de magl | |
| MA60099B1 (fr) | Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1 | |
| MA60100B1 (fr) | Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1 | |
| MA27844A1 (fr) | Derives pyrroliques substitues | |
| MA58653A1 (fr) | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 | |
| MA29694B1 (fr) | Derives de l'imidazopyridine comme ligands du recepteur cannabinoide |